drugset / Trial / NCT01581853

Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily

NCT01581853

Phase 4 Completed 21 enrolled Daniel Podzamczer
NaSingle-groupOpen-labelTreatment

Summary

Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago. The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200 mg monotherapy once a day.

Timeline

Start
2012-05
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lopinavir Other / unclassified 800 mg
Subject Ritonavir Other / unclassified 200 mg